Switch to:
Also traded in: France, Germany, Italy, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt N/A
SNY's Cash to Debt is ranked lower than
73% of the 763 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. SNY: N/A )
Ranked among companies with meaningful Cash to Debt only.
SNY' s Cash to Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.56 Max: 10.62
Current: N/A
0.14
10.62
Equity to Asset 0.57
SNY's Equity to Asset is ranked lower than
57% of the 701 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. SNY: 0.57 )
Ranked among companies with meaningful Equity to Asset only.
SNY' s Equity to Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.58 Max: 0.65
Current: 0.57
0.48
0.65
Interest Coverage 9.68
SNY's Interest Coverage is ranked lower than
67% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.94 vs. SNY: 9.68 )
Ranked among companies with meaningful Interest Coverage only.
SNY' s Interest Coverage Range Over the Past 10 Years
Min: 8.34  Med: 12.02 Max: 19.65
Current: 9.68
8.34
19.65
F-Score: 5
Z-Score: 1.95
M-Score: -2.34
WACC vs ROIC
8.55%
12.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 15.86
SNY's Operating margin (%) is ranked higher than
73% of the 708 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.77 vs. SNY: 15.86 )
Ranked among companies with meaningful Operating margin (%) only.
SNY' s Operating margin (%) Range Over the Past 10 Years
Min: 15.25  Med: 18.29 Max: 20.7
Current: 15.86
15.25
20.7
Net-margin (%) 12.84
SNY's Net-margin (%) is ranked higher than
71% of the 711 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.28 vs. SNY: 12.84 )
Ranked among companies with meaningful Net-margin (%) only.
SNY' s Net-margin (%) Range Over the Past 10 Years
Min: 11.16  Med: 14.35 Max: 18.02
Current: 12.84
11.16
18.02
ROE (%) 12.74
SNY's ROE (%) is ranked higher than
68% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.97 vs. SNY: 12.74 )
Ranked among companies with meaningful ROE (%) only.
SNY' s ROE (%) Range Over the Past 10 Years
Min: 6.51  Med: 8.75 Max: 11.7
Current: 12.74
6.51
11.7
ROA (%) 7.31
SNY's ROA (%) is ranked higher than
67% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. SNY: 7.31 )
Ranked among companies with meaningful ROA (%) only.
SNY' s ROA (%) Range Over the Past 10 Years
Min: 3.78  Med: 5.46 Max: 7.04
Current: 7.31
3.78
7.04
ROC (Joel Greenblatt) (%) 58.74
SNY's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 757 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.44 vs. SNY: 58.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SNY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 31.74  Med: 42.80 Max: 63.92
Current: 58.74
31.74
63.92
Revenue Growth (3Y)(%) -1.10
SNY's Revenue Growth (3Y)(%) is ranked lower than
70% of the 594 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. SNY: -1.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SNY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.1  Med: 6.35 Max: 27.3
Current: -1.1
-3.1
27.3
EBITDA Growth (3Y)(%) -3.90
SNY's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 545 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. SNY: -3.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SNY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.8  Med: 3.30 Max: 48.8
Current: -3.9
-9.8
48.8
EPS Growth (3Y)(%) -3.40
SNY's EPS Growth (3Y)(%) is ranked lower than
67% of the 501 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. SNY: -3.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SNY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -13.4  Med: 1.70 Max: 41.4
Current: -3.4
-13.4
41.4
» SNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

SNY Guru Trades in Q2 2015

Lee Ainslie 101,650 sh (New)
John Buckingham 132,190 sh (+437.18%)
Dodge & Cox 49,765,693 sh (+15.64%)
Manning & Napier Advisors, Inc 2,879,307 sh (+15.20%)
Sarah Ketterer 516,115 sh (+8.12%)
Scott Black 178,437 sh (+1.60%)
Ken Fisher 13,246,593 sh (+1.44%)
Warren Buffett 3,905,875 sh (unchged)
David Dreman 1,102 sh (unchged)
Bill Nygren 5,670,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
Mario Gabelli 4,700 sh (unchged)
Paul Tudor Jones Sold Out
Charles Brandes 2,560,460 sh (-0.52%)
Murray Stahl 26,000 sh (-0.71%)
Barrow, Hanley, Mewhinney & Strauss 29,961,207 sh (-0.87%)
PRIMECAP Management 3,756,457 sh (-5.45%)
HOTCHKIS & WILEY 10,701,542 sh (-9.17%)
NWQ Managers 2,636,361 sh (-32.87%)
» More
Q3 2015

SNY Guru Trades in Q3 2015

Paul Tudor Jones 5,809 sh (New)
Sarah Ketterer 574,783 sh (+11.37%)
Murray Stahl 27,000 sh (+3.85%)
John Buckingham 133,116 sh (+0.70%)
Ken Fisher 13,295,966 sh (+0.37%)
Dodge & Cox 49,859,813 sh (+0.19%)
Lee Ainslie 101,650 sh (unchged)
Francis Chou 410,000 sh (unchged)
Mario Gabelli 4,700 sh (unchged)
David Dreman 1,102 sh (unchged)
Bill Nygren 5,670,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Manning & Napier Advisors, Inc 2,819,031 sh (-2.09%)
Scott Black 173,432 sh (-2.80%)
Barrow, Hanley, Mewhinney & Strauss 29,123,564 sh (-2.80%)
NWQ Managers 2,501,826 sh (-5.10%)
Charles Brandes 2,290,031 sh (-10.56%)
HOTCHKIS & WILEY 9,035,695 sh (-15.57%)
PRIMECAP Management 2,939,082 sh (-21.76%)
» More
Q4 2015

SNY Guru Trades in Q4 2015

HOTCHKIS & WILEY 10,141,383 sh (+12.24%)
Murray Stahl 28,300 sh (+4.81%)
Barrow, Hanley, Mewhinney & Strauss 29,489,368 sh (+1.26%)
Ken Fisher 13,416,220 sh (+0.90%)
Dodge & Cox 49,915,073 sh (+0.11%)
Mario Gabelli 4,700 sh (unchged)
Paul Tudor Jones 5,809 sh (unchged)
Francis Chou 410,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Bill Nygren 5,670,000 sh (unchged)
Scott Black Sold Out
David Dreman Sold Out
Charles Brandes 2,198,827 sh (-3.98%)
PRIMECAP Management 2,767,582 sh (-5.84%)
John Buckingham 124,012 sh (-6.84%)
Lee Ainslie 91,300 sh (-10.18%)
NWQ Managers 2,078,119 sh (-16.94%)
Sarah Ketterer 428,923 sh (-25.38%)
Manning & Napier Advisors, Inc 281,917 sh (-90.00%)
» More
Q1 2016

SNY Guru Trades in Q1 2016

Ken Fisher 13,546,950 sh (+0.97%)
Murray Stahl 27,697 sh (-2.13%)
Manning & Napier Advisors, Inc 275,505 sh (-2.27%)
» More
» Details

Insider Trades

Latest Guru Trades with SNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Sanofi SA

Sanofi's New Products Will Fuel Sales Company is developing vaccine for Zika virus
One of the most prominent stocks that most investors like to keep in their portfolios is Sanofi. (NYSE:SNY). Among the gurus, James Barrow (Trades, Portfolio) is one of the largest shareholders of the stock and some of the other prominent investors who hold a position in Sanofi are Ken Fisher (Trades, Portfolio), Bill Nygren (Trades, Portfolio) and Warren Buffett. Read more...
Weekly 3-Year Low Highlights: Sanofi, Exelon, Cummins, W.W. Grainger A look at companies whose stocks have recently reached their 3-year lows
According to GuruFocus list of 3-year lows, Sanofi (NYSE:SNY), Exelon Corp. (NYSE:EXC), Cummins Inc. (NYSE:CMI) and W.W. Grainger Inc. (NYSE:GWW) have all reached their three-year lows. Read more...
John Buckingham Buys 10 New Stakes in Second Quarter
John Buckingham (Trades, Portfolio), chief investment officer of AFAM (Al Frank Asset Management) Capital, which specializes in managing exchange-traded funds and equity portfolios, and editor of The Prudent Investor, an investment newsletter, learned the ropes from value investor Al Frank. The Al Frank Fund posted returns of 5.47% in 2014, 37.06% in 2013 and 17.26% in 2012. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 21.26
SNY's P/E(ttm) is ranked higher than
62% of the 542 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.66 vs. SNY: 21.26 )
Ranked among companies with meaningful P/E(ttm) only.
SNY' s P/E(ttm) Range Over the Past 10 Years
Min: 9.64  Med: 20.89 Max: 38.97
Current: 21.26
9.64
38.97
Forward P/E 12.52
SNY's Forward P/E is ranked higher than
62% of the 69 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.86 vs. SNY: 12.52 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 21.26
SNY's PE(NRI) is ranked higher than
62% of the 539 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.62 vs. SNY: 21.26 )
Ranked among companies with meaningful PE(NRI) only.
SNY' s PE(NRI) Range Over the Past 10 Years
Min: 9.82  Med: 20.86 Max: 39.2
Current: 21.26
9.82
39.2
P/B 1.56
SNY's P/B is ranked higher than
73% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. SNY: 1.56 )
Ranked among companies with meaningful P/B only.
SNY' s P/B Range Over the Past 10 Years
Min: 1.11  Med: 1.69 Max: 2.38
Current: 1.56
1.11
2.38
P/S 2.67
SNY's P/S is ranked higher than
51% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. SNY: 2.67 )
Ranked among companies with meaningful P/S only.
SNY' s P/S Range Over the Past 10 Years
Min: 1.72  Med: 2.81 Max: 3.94
Current: 2.67
1.72
3.94
EV-to-EBIT 17.20
SNY's EV-to-EBIT is ranked higher than
56% of the 525 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.51 vs. SNY: 17.20 )
Ranked among companies with meaningful EV-to-EBIT only.
SNY' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.3  Med: 19.30 Max: 200.9
Current: 17.2
8.3
200.9
EV-to-EBITDA 12.55
SNY's EV-to-EBITDA is ranked higher than
64% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.66 vs. SNY: 12.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
SNY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.4  Med: 12.80 Max: 129.7
Current: 12.55
5.4
129.7
Shiller P/E 19.56
SNY's Shiller P/E is ranked higher than
85% of the 145 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.10 vs. SNY: 19.56 )
Ranked among companies with meaningful Shiller P/E only.
SNY' s Shiller P/E Range Over the Past 10 Years
Min: 12.53  Med: 21.30 Max: 28.21
Current: 19.56
12.53
28.21
Current Ratio 1.72
SNY's Current Ratio is ranked lower than
66% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. SNY: 1.72 )
Ranked among companies with meaningful Current Ratio only.
SNY' s Current Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.72 Max: 2.71
Current: 1.72
0.79
2.71
Quick Ratio 1.36
SNY's Quick Ratio is ranked lower than
64% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. SNY: 1.36 )
Ranked among companies with meaningful Quick Ratio only.
SNY' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 1.26 Max: 2.41
Current: 1.36
0.46
2.41
Days Inventory 139.55
SNY's Days Inventory is ranked lower than
61% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.30 vs. SNY: 139.55 )
Ranked among companies with meaningful Days Inventory only.
SNY' s Days Inventory Range Over the Past 10 Years
Min: 170.45  Med: 185.70 Max: 378.14
Current: 139.55
170.45
378.14
Days Sales Outstanding 79.53
SNY's Days Sales Outstanding is ranked lower than
53% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.16 vs. SNY: 79.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
SNY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.19  Med: 71.40 Max: 83.73
Current: 79.53
61.19
83.73
Days Payable 131.68
SNY's Days Payable is ranked higher than
76% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.22 vs. SNY: 131.68 )
Ranked among companies with meaningful Days Payable only.
SNY' s Days Payable Range Over the Past 10 Years
Min: 99.74  Med: 128.93 Max: 326.59
Current: 131.68
99.74
326.59

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.00
SNY's Dividend Yield is ranked higher than
89% of the 565 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.56 vs. SNY: 4.00 )
Ranked among companies with meaningful Dividend Yield only.
SNY' s Dividend Yield Range Over the Past 10 Years
Min: 1.7  Med: 3.70 Max: 5.46
Current: 4
1.7
5.46
Dividend Payout 0.87
SNY's Dividend Payout is ranked lower than
88% of the 371 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. SNY: 0.87 )
Ranked among companies with meaningful Dividend Payout only.
SNY' s Dividend Payout Range Over the Past 10 Years
Min: 0.27  Med: 0.59 Max: 1.02
Current: 0.87
0.27
1.02
Dividend Growth (3y) 2.50
SNY's Dividend Growth (3y) is ranked lower than
62% of the 283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. SNY: 2.50 )
Ranked among companies with meaningful Dividend Growth (3y) only.
SNY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 6.45 Max: 29.6
Current: 2.5
0
29.6
Forward Dividend Yield 3.96
SNY's Forward Dividend Yield is ranked higher than
88% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. SNY: 3.96 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.77
SNY's Yield on cost (5-Year) is ranked higher than
82% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.98 vs. SNY: 4.77 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SNY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.03  Med: 4.42 Max: 6.52
Current: 4.77
2.03
6.52

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 14.22
SNY's Price/Tangible Book is ranked lower than
91% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. SNY: 14.22 )
Ranked among companies with meaningful Price/Tangible Book only.
SNY' s Price/Tangible Book Range Over the Past 10 Years
Min: 7.22  Med: 14.15 Max: 41.94
Current: 14.22
7.22
41.94
Price/Projected FCF 3.86
SNY's Price/Projected FCF is ranked higher than
78% of the 300 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.69 vs. SNY: 3.86 )
Ranked among companies with meaningful Price/Projected FCF only.
SNY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.92  Med: 1.23 Max: 1.56
Current: 3.86
0.92
1.56
Price/Median PS Value 0.95
SNY's Price/Median PS Value is ranked higher than
65% of the 637 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.16 vs. SNY: 0.95 )
Ranked among companies with meaningful Price/Median PS Value only.
SNY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.64  Med: 1.08 Max: 2.69
Current: 0.95
0.64
2.69
Price/Graham Number 3.69
SNY's Price/Graham Number is ranked lower than
76% of the 446 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.09 vs. SNY: 3.69 )
Ranked among companies with meaningful Price/Graham Number only.
SNY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.92  Med: 4.34 Max: 6.63
Current: 3.69
1.92
6.63
Earnings Yield (Greenblatt) (%) 5.80
SNY's Earnings Yield (Greenblatt) (%) is ranked higher than
69% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. SNY: 5.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SNY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 5.20 Max: 12
Current: 5.8
0.5
12
Forward Rate of Return (Yacktman) (%) -3.95
SNY's Forward Rate of Return (Yacktman) (%) is ranked lower than
70% of the 316 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.27 vs. SNY: -3.95 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SNY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -6.1  Med: 16.80 Max: 44.3
Current: -3.95
-6.1
44.3

More Statistics

Revenue(Mil) $39170
EPS $ 1.83
Beta1.01
Short Percentage of Float0.18%
52-Week Range $37.63 - 54.98
Shares Outstanding(Mil)2611.39

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 40,737 40,992 43,695
EPS($) 3.01 3.06 3.37
EPS without NRI($) 3.01 3.06 3.37

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:JNJ, NYSE:PFE, XSWX:NOVN, NYSE:MRK, NYSE:BMY » details
Traded in other countries:SAN.France, SNW.Germany, SANF.Italy, SNYN.Mexico, SAN.Switzerland, 0O59.UK, SNYNF.USA,
Sanofi SA was incorporated under the laws of France on April 28,1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.
» More Articles for SNY

Headlines

Articles On GuruFocus.com
Warren Buffett’s Top 5 Dividend Yielding Stocks Apr 26 2016 
Manning & Napier Sells Chunks of Stakes in GE, Eli Lilly, Merck Mar 29 2016 
Amgen: Should I Just Sit and Wait? Mar 18 2016 
Sanofi's New Products Will Fuel Sales Mar 13 2016 
Warren Buffett's Worst Performing Stocks Mar 03 2016 
Dodge & Cox Global Stock Fund 4th Quarter Commentary Jan 19 2016 
Dodge & Cox Stock Fund 2015 Commentary Jan 18 2016 
Why MannKind Could Be a Value Trap Jan 04 2016 
Francis Chou's Holdings Trading at Low PE Dec 23 2015 
Warren Buffett Further Pares Munich Re Stake Dec 14 2015 

More From Other Websites
Interest Rises in Medivation Oncology Prospects May 04 2016
ETF’s with exposure to Sanofi : May 4, 2016 May 04 2016
Medivation rises amid possible Pfizer takeover bid May 04 2016
Sanofi sees "strong strategic" fit with U.S. Medivation May 04 2016
Pfizer eyes this San Francisco biotech involved in tight acquisition war May 04 2016
Will a Third Medivation Suitor Present Itself? May 04 2016
Medivation (MDVN) Stock Climbs on Potential Pfizer Deal May 04 2016
Sanofi: Annual General Shareholder Meeting of May 4, 2016 May 04 2016
Sanofi says sees 'strong strategic' fit with Medivation May 04 2016
Sanofi says sees "strong strategic" fit with U.S. cancer firm Medivation May 04 2016
Who Will Win Medivation: Pfizer or Sanofi? May 04 2016
EXCLUSIVE: Pfizer approaches Medivation about potential takeover -sources May 03 2016
EXCLUSIVE: Pfizer approaches Medivation about potential takeover -sources May 03 2016
Forget Allergan: Pfizer Has Its Sights On This Cancer Drugmaker May 03 2016
Relypsa Taps Debt Market: Yeah, That’s Bullish May 03 2016
Exclusive: Pfizer approaches Medivation about potential takeover - sources May 03 2016
Baby Powder Cancer Suits Cloud Johnson and Johnson May 03 2016
Hulu Takes Aim at DISH and Sony in Live Streaming May 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK